Maplight Therapeutics (NASDAQ:MPLT) Trading 5.3% Higher – Still a Buy?

Posted by Francis Steltz on Sep 1st, 2026

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report)’s stock price traded up 5.3% during mid-day trading on Tuesday . The stock traded as high as $13.60 and last traded at $13.66. Approximately 216,826 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 464,878 shares. The stock had previously closed at $12.97.

Wall Street Analysts Forecast Growth

MPLT has been the subject of several research analyst reports. Lifesci Capital raised Maplight Therapeutics to a “strong-buy” rating in a research report on Thursday, May 14th. Craig Hallum reaffirmed a “buy” rating and issued a $25.00 price target on shares of Maplight Therapeutics in a research report on Tuesday, July 28th. Morgan Stanley reiterated an “equal weight” rating and set a $21.00 price target (down from $34.00) on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maplight Therapeutics in a research report on Monday, July 13th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Maplight Therapeutics in a research note on Monday, July 27th. Four analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Maplight Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Read Our Latest Stock Report on MPLT

Maplight Therapeutics Stock Performance

The firm’s 50-day moving average price is $23.63 and its two-hundred day moving average price is $24.10. The firm has a market capitalization of $629.81 million and a price-to-earnings ratio of -0.32.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.08. As a group, equities research analysts anticipate that Maplight Therapeutics, Inc. will post -5.12 EPS for the current year.

Insiders Place Their Bets

In other news, insider James Woodruff Lillie sold 22,082 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $12.54, for a total value of $276,908.28. Following the sale, the insider owned 202,380 shares in the company, valued at approximately $2,537,845.20. The trade was a 9.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Cox bought 15,620 shares of the stock in a transaction dated Tuesday, July 28th. The stock was purchased at an average cost of $9.52 per share, for a total transaction of $148,702.40. Following the acquisition, the director owned 15,620 shares in the company, valued at $148,702.40. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 3.80% of the stock is currently owned by company insiders.

Institutional Trading of Maplight Therapeutics

Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new stake in shares of Maplight Therapeutics during the second quarter worth approximately $37,000. Strs Ohio acquired a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $53,000. Bank of New York Mellon Corp grew its position in Maplight Therapeutics by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock worth $802,000 after acquiring an additional 3,608 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Maplight Therapeutics during the 4th quarter worth approximately $70,000. Finally, California State Teachers Retirement System increased its holdings in Maplight Therapeutics by 386.0% during the 2nd quarter. California State Teachers Retirement System now owns 5,161 shares of the company’s stock valued at $185,000 after purchasing an additional 4,099 shares in the last quarter.

Maplight Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.